Sammy@NeuroSGS
Many studies report “brain shrinkage” in trans women on feminizing hormone therapy, typically seen by reductions in MRI-derived volume and an increase in the ventricular space. One mechanistic interpretation for this is “cellular shrinkage” driven by changes in water balance.
Estradiol treatment modulates Astrocyte physiology, including ion transport and metabolic activity, and can reduce Aquaporin-4 expression. These factors together influence intracellular osmolarity and the ease with which water moves across cell membranes.
If intracellular osmolarity decreases relative to the surrounding environment (e.g., via ion redistribution or metabolic shifts), water will move out of cells along osmotic gradients. With reduced AQP4, cells may also be less able to rapidly re-equilibrate water. The net effect can be “cellular dehydration” and “shrinkage” of neurons and/or astrocytes.
At the tissue level, widespread but subtle cell shrinkage reduces overall volume, which MRI detects as decreased cortical size. This does not imply cell death; rather, it reflects a biophysical change in cell size and hydration state.
Functionally, this points to altered fluid and ionic homeostasis in the treatment-affected trans woman brain rather than degeneration per se.
Thus, “shrinkage” can plausibly be understood as osmotic cell volume regulation under altered hormonal conditions, mediated by astrocyte–vascular interactions, rather than structural loss of brain tissue.
Citation:
pubmed.ncbi.nlm.nih.gov/40145530/
